New Quinoline-Based Proteasome Inhibitors

 

Executive Summary

 

There are several existing cancer treatments that are effective at inducing cell death by decreasing proteasome activity: Velcade® (bortezomib) and Kyprolis® (carfilzomib). Due to undesirable side effects and pharmacodynamics properties, these agents have been limited to treating blood cancers.  MSU researchers have developed a new class of therapeutic compounds with a unique mode of action and more promising pharmacodynamics. 

 

Description of Technology

 

This technology uses a new class of quinoline-based proteasome inhibitors. These compounds differ from previous proteasome inhibitors by exhibiting uncompetitive reversible inhibition rather than competitive inhibition. This technology is effective against bortezomib-resistant Multiple Myeloma cells and has potential as a novel asthma treatment.

 

Key Benefits

  • Effective against drug-resistant myeloma cells
  • Has potential to target other cancers and diseases
  • Novel mechanism of inhibition
  • Simple chemical synthesis

 

Applications

  • Treating Multiple Myeloma
    • Inhibit proteasome function to kill cancer cell
    • Effective against bortezomib-resistant strains
  • Treating asthma
    • Same inhibition pathway

 

Patent Status: 

 

Under review

 

Licensing Rights Available

 

Full licensing rights available

 

Inventors: Aaron Odom, Jetze Tepe, Teri Lansdall

 

Tech ID: TEC2016-0123

 

Alternative contact due to temporary leave:

 

Nina (Isi) Davis, Technology Marketing Manager, email: davisnin@msu.edu, phone (direct): (517)884-1829. 

 

Patent Information:

Category(s):

For Information, Contact:

Anne DiSante
Associate Director
Michigan State University
disante@msu.edu
Keywords: